Cho Junhun, Kim Kyoung-Mee, Kim Hee Cheol, Lee Woo Yong, Kang Won Ki, Park Young Suk, Ha Sang Yun
Department of Pathology and Translational Genomics, Seoul, Republic of Korea.
Department of Surgery, Seoul, Republic of Korea.
Pathol Res Pract. 2019 Jan;215(1):171-176. doi: 10.1016/j.prp.2018.10.024. Epub 2018 Oct 24.
Tumor associated glycoprotein 72 (TAG-72) is a membrane-bound glycoprotein complex that is overexpressed in many adenocarcinomas. Recently, monoclonal antibody targeting TAG72, minretumomab, have been introduced as a potential therapeutic target in colorectal cancers (CRC) as well as breast and lung cancers. However, the detailed expression profile of TAG72 and its prognostic effect in CRC are not clear yet. We investigated the relationship between tumor associated glycoprotein 72 (TAG-72) expression and clinicopathologic characteristics in CRC using 3E8 antibody, a fully humanized antibody with the highest affinity to TAG-72. Immunohistochemical staining for TAG-72 was performed in 578 CRC patients, and the results were analyzed using a modified Remmele scoring system (score: 0-12). Of the 578 patients, 144 (24.9%) composed the TAG-72 overexpression (TAG-72) group. TAG-72 was significantly associated with microsatellite stable tumor (P = .002), lymphatic invasion (P = .001), venous invasion (P = .005), and high pN status (P < .001). In survival analyses, TAG-72 group showed shorter disease-free survival in univariate analysis (P = .001), and TAG-72 was found to be an independent prognostic factor in multivariate analysis (P = .028), in addition to TNM stage. In conclusion, TAG-72 is thought to be the factors involved in the progression of CRC and may be considered as one of the potential therapeutic target.
肿瘤相关糖蛋白72（TAG-72）是一种膜结合糖蛋白复合物，在许多腺癌中过度表达。最近，靶向TAG72的单克隆抗体米瑞妥单抗已被引入作为结直肠癌（CRC）以及乳腺癌和肺癌的潜在治疗靶点。然而，TAG72在CRC中的详细表达谱及其预后作用尚不清楚。我们使用对TAG-72具有最高亲和力的全人源化抗体3E8，研究了结直肠癌中肿瘤相关糖蛋白72（TAG-72）表达与临床病理特征之间的关系。对578例CRC患者进行了TAG-72的免疫组织化学染色，并使用改良的雷姆勒评分系统（评分：0-12）分析结果。在578例患者中，144例（24.9%）组成TAG-72过表达（TAG-72）组。TAG-72与微卫星稳定肿瘤（P = 0.002）、淋巴浸润（P = 0.001）、静脉浸润（P = 0.005）和高pN状态（P < 0.001）显著相关。在生存分析中，TAG-72组在单因素分析中显示无病生存期较短（P = 0.001），并且除TNM分期外，TAG-72在多因素分析中被发现是一个独立的预后因素（P = 0.028）。总之，TAG-72被认为是参与CRC进展的因素，可能被视为潜在的治疗靶点之一。
